Substitute for form 1449A/PTO Complete if Known 10/634,431 **Application Number** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date August 5, 2003 NOV ;O First Name Inventor Guba 2003 (Use several sheets if necessary) 1626 **Group Art Unit** Stockton **Examiner Name** Attorney Docket Number of 2 21152 **U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Applicant of Cite Examiner Date of Publication of Kind Code² No.1 Initials' Cited Document Cited document Number (if known) **MM-DD-YYYY** B 4,598,089 A1 Hadvary, et. al. 07/01/1986 3 **A2** 6,004,996 Shah, et. al. 12/21/1999 8 **A3** 2001/0039275 Bowler, et. al. 11/08/2001 B A4 4,931,463 Barbier, et. al. 06/05/1990 B Barbier, et. al. **A5** 4,983,746 01/08/1991 189 888 **A6** 5,399,720 Karph, et. al. 03/21/1995 4,035,367 Simpson, William R. **A7** 07/12/1977 ARP. **A8** Niewohner, et. al. 6,573,263 06/03/2003 FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of **T** Name of Patentee or Examiner Cite Cited Document Office³ Kind Code³ Number Applicant of Cited Document Initials' No.' MM-DD-YYYY (if known) F. Hoffmann-La EP 185,359 **B**1 06-25-1986 Roche & Co. B2 EP 189,577 F. Hoffmann-La 08-06-1986 Roche AG **B**3 EP 443,449 F. Hoffmann-La 08-28-1991 R Roche AG F. Hoffmann-La **B**4 EP 524,495 01-27-1993 SEC. Roche AG WO99/34786 Geltex **B**5 07-15-1999 28-Pharmaceuticals, Inc. WO 00/09123 **B6** F. Hoffmann-La 02-24-2000 粉 Roche AG WO 00/09122 F. Hoffmann-La **B7** 02-24-2000 B Roche AG **B8** WO 99 62892 12-09-1999 Novartis Erfind 23 Verwalt GMBH; Norvartis AG WO 01 64675 **B9** 09-07-2001 Norvartis Erfind SR. Verwalt GMBH; Norvartis AG

F. Hoffmann-La

F. Hoffmann-La

Roche AG

Roche AG

03/14/2002

11/28/2002

WO 02 20488

WO 02 094789

B10

B11

Elle-

Be

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/634,431 NFORMATION DISCLOSURE ATEMENT BY APPLICANT Filing Date August 5, 2003 First Name Inventor Guba (Use several sheets if necessary) **Group Art Unit** 626 **Examiner Name** Attorney Docket Number of 2 21152

· &	B12	WO 96 37474	Warner-Lambert	11/28/1996	
, <i>3tD</i>			Company		
83	B13	WO 01 23389	Neurogen Corporation	04/05/2001	
888	B14	WO 2003011843	Bowler, et. al.	02/13/2003	

							•		_
Examiner		0		11 _		Date Considered		I _]
Examine	A-0.		TEN			Date Considered	1312	175	
Signature	\triangle								
A 100 A 4 2 A 100 A 100 A				1.5 A 4 D 2 D 4 A 4 D	4	'A ' A '			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

135542

多等。 《

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO					Complete if Known				
JC708NFORMATION DISCLOSURE				SURE	Application Number	10/634,	10/634,431		
STORMATION DISCLOSURE STORMATION DISCLOSURE					Filing Date	August	August 5, 2003		
& Ding	E July H				First Name Inventor	Guba			
V	Suse several sheets if necessary)				Group Art Unit	1614	1614. 626		
	3				Examiner Name		Stockton		
Sheet	neet of 1			Attorney Docket Number					
				U.S. PAT	ENT DOCUMENTS	21152			
		U.S. Patent Document					T		
Examiner	Cite No.1			Kind Code ²	Name of Patentee or App		Date of Publicati	e of Publication of	
Initials'		Number		(if known)	Cited Document		Cited docume		
							MM-DD-YY	D-YYYY	
		<u> </u>							
						<u>.</u>			
						, _, .		,	
		<u> </u>							
	<u> </u>		· • • •						
						•		· ·	
				· ·					
					-			 -{	
			* *** <u></u>						
	<u> </u>				ATENT DOCUMENTS			1	
Examiner Cite Foreign Patent Document				cument	Name of Patentee or	te of Publication of T			
Initials'	No.'	Office Number Kind Code			Applicant of Cited Docur	Cited Document MM-DD-YYYY			
		(if known)							
<i>w</i> 2	B15	WO 99 21845) ————————————————————————————————————	Agouron Pharma		05-06-1999		
									
-						·			
		-					<u> </u>		
*								┟—┤	
									
				· · · · · · · · · · · · · · · · · · ·					
				· · · · · · · · · · · · · · · · · · ·	1			$\vdash \vdash \vdash$	
Examiner		-Date C	Considered	,0_		1.~		1	
Signature		X	~uu~	A.C.	JE 32	100			

Signature 32 9

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through chation if not in conformance and not considered. Include copy of this form with next communication to applicate.

form with next communication to applicant.

**Unique citation designation number. **See attached Kinds of U.S. Patent Documents. **Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.